Risk factors for intracranial hemorrhage in acute ischemic stroke patients treated with recombinant tissue plasminogen activator: a systematic review and meta-analysis of 55 studies

William N. Whiteley*, Karsten Bruins Slot, Peter Fernandes, Peter Sandercock, Joanna Wardlaw

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND AND PURPOSE: Recombinant tissue plasminogen activator (rtPA) is an effective treatment for acute ischemic stroke but is associated with an increased risk of intracranial hemorrhage (ICH). We sought to identify the risk factors for ICH with a systematic review of the published literature.

METHODS: We searched for studies of rtPA-treated stroke patients that reported an association between a variable measured before rtPA infusion and clinically important ICH (parenchymal ICH or ICH associated with clinical deterioration). We calculated associations between baseline variables and ICH with random-effect meta-analyses.

RESULTS: We identified 55 studies that measured 43 baseline variables in 65 264 acute ischemic stroke patients. Post-rtPA ICH was associated with higher age (odds ratio, 1.03 per year; 95% confidence interval, 1.01-1.04), higher stroke severity (odds ratio, 1.08 per National Institutes of Health Stroke Scale point; 95% confidence interval, 1.06-1.11), and higher glucose (odds ratio, 1.10 per mmol/L; 95% confidence interval, 1.05-1.14). There was approximately a doubling of the odds of ICH with the presence of atrial fibrillation, congestive heart failure, renal impairment, previous antiplatelet agents, leukoaraiosis, and a visible acute cerebral ischemic lesion on pretreatment brain imaging. Little of the variation in the sizes of the associations among different studies was explained by the source of the cohort, definition of ICH, or degree of adjustment for confounding variables.

CONCLUSIONS: Individual baseline variables were modestly associated with post-rtPA ICH. Prediction of post-rtPA ICH therefore is likely to be difficult if based on single clinical or imaging factors alone. These observational data do not provide a reliable method for the individualization of treatment according to predicted ICH risk.

Original languageEnglish
Pages (from-to)2904-2909
Number of pages6
JournalStroke
Volume43
Issue number11
DOIs
Publication statusPublished - Nov 2012

Keywords

  • INTRAVENOUS THROMBOLYSIS
  • MANAGEMENT
  • thrombolysis
  • SCORE
  • GUIDELINES
  • OUTCOMES
  • meta-analysis
  • THROMBOLYTIC THERAPY
  • ECASS
  • SITS-MOST
  • ALTEPLASE
  • SAFE IMPLEMENTATION
  • acute stroke
  • systematic review

Cite this